{"transactions":[{"id":758533,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:30:18.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":20582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":20582,"derivative":{"exercise_price":8.59,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":20582},"source":{"system":"sec-edgar","filing":"0001193125-26-248435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000119312526248435/ownership.xml","form_type":"4"}},{"id":758532,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:30:18.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001193125-26-248435","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000119312526248435/ownership.xml","form_type":"4"}},{"id":758531,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:30:15.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":20582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":20582,"derivative":{"exercise_price":8.59,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":20582},"source":{"system":"sec-edgar","filing":"0001193125-26-248434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000119312526248434/ownership.xml","form_type":"4"}},{"id":758530,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:30:15.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001193125-26-248434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000119312526248434/ownership.xml","form_type":"4"}},{"id":758581,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:30:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":20582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":20582,"derivative":{"exercise_price":8.59,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":20582},"source":{"system":"sec-edgar","filing":"0001193125-26-248429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000119312526248429/ownership.xml","form_type":"4"}},{"id":758580,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:30:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001193125-26-248429","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000119312526248429/ownership.xml","form_type":"4"}},{"id":758376,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairperson"}}],"security":"Common Stock","published_at":"2026-05-29T20:30:04.000Z","date":"2026-05-27","kind":"tax_withholding","planned":false,"acquired":false,"shares":4194,"price":8.59,"value":36026.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by and surrendered to the Issuer on May 27, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock unit award for 16,634 shares that vested in full on May 27, 2026."}],"balance_after":66741,"source":{"system":"sec-edgar","filing":"0001193125-26-248427","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000119312526248427/ownership.xml","form_type":"4"}},{"id":759002,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43234,"kind":"person","name":"Aktar Mert","position":1,"cik":"0002040256","reported_name":"Aktar Mert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-29T20:30:02.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":20582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":20582,"derivative":{"exercise_price":8.59,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":20582},"source":{"system":"sec-edgar","filing":"0001193125-26-248425","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040256/000119312526248425/ownership.xml","form_type":"4"}},{"id":759001,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43234,"kind":"person","name":"Aktar Mert","position":1,"cik":"0002040256","reported_name":"Aktar Mert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-29T20:30:02.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":5093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":21727,"source":{"system":"sec-edgar","filing":"0001193125-26-248425","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040256/000119312526248425/ownership.xml","form_type":"4"}},{"id":770304,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":45734,"kind":"person","name":"Martini Gregory S.","position":1,"cik":"0002053936","reported_name":"Martini Gregory S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-20T20:30:08.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on May 18, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's\ncontinuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":325000,"derivative":{"exercise_price":8.54,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001193125-26-232681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2053936/000119312526232681/ownership.xml","form_type":"4"}},{"id":789426,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":49327,"kind":"person","name":"Dac Nadia","position":1,"cik":"0001773151","reported_name":"Dac Nadia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-06T20:30:09.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on May 4, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive"}],"balance_after":300000,"derivative":{"exercise_price":9,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-209120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1773151/000119312526209120/ownership.xml","form_type":"4"}},{"id":836628,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":59798,"kind":"person","name":"GRASSO MARC","position":1,"cik":"0001748894","reported_name":"GRASSO MARC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-17T16:30:36.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65000,"derivative":{"exercise_price":8.95,"expiration_date":"2036-03-13","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001193125-26-110934","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748894/000119312526110934/ownership.xml","form_type":"4"}},{"id":836627,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":59798,"kind":"person","name":"GRASSO MARC","position":1,"cik":"0001748894","reported_name":"GRASSO MARC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T16:30:36.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-110934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748894/000119312526110934/ownership.xml","form_type":"4"}},{"id":838653,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60094,"kind":"person","name":"Biddle Warner Weston","position":1,"cik":"0002034523","reported_name":"Biddle Warner Weston","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-17T16:30:12.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":350000,"derivative":{"exercise_price":8.95,"expiration_date":"2036-03-13","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001193125-26-110920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2034523/000119312526110920/ownership.xml","form_type":"4"}},{"id":838652,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60094,"kind":"person","name":"Biddle Warner Weston","position":1,"cik":"0002034523","reported_name":"Biddle Warner Weston","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-17T16:30:12.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":58000,"source":{"system":"sec-edgar","filing":"0001193125-26-110920","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034523/000119312526110920/ownership.xml","form_type":"4"}},{"id":838699,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60105,"kind":"person","name":"GEHCHAN NAJI","position":1,"cik":"0002052410","reported_name":"GEHCHAN NAJI","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-17T16:30:10.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":105000,"derivative":{"exercise_price":8.95,"expiration_date":"2036-03-13","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-110941","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2052410/000119312526110941/ownership.xml","form_type":"4"}},{"id":838698,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60105,"kind":"person","name":"GEHCHAN NAJI","position":1,"cik":"0002052410","reported_name":"GEHCHAN NAJI","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-17T16:30:10.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001193125-26-110941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2052410/000119312526110941/ownership.xml","form_type":"4"}},{"id":861725,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-04T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":42945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":42945,"derivative":{"exercise_price":7.95,"expiration_date":"2036-02-24","underlying":"Common Stock","underlying_shares":42945},"source":{"system":"sec-edgar","filing":"0001193125-26-091626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000119312526091626/ownership.xml","form_type":"4"}},{"id":861724,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43219,"kind":"person","name":"Miller Andrew Craig","position":1,"cik":"0001777760","reported_name":"Miller Andrew Craig","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-04T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":11006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":11006,"source":{"system":"sec-edgar","filing":"0001193125-26-091626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777760/000119312526091626/ownership.xml","form_type":"4"}},{"id":879184,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37711,"kind":"person","name":"Emany Sravan Kumar","position":1,"cik":"0001897662","reported_name":"Emany Sravan Kumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":42945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":42945,"derivative":{"exercise_price":7.95,"expiration_date":"2036-02-24","underlying":"Common Stock","underlying_shares":42945},"source":{"system":"sec-edgar","filing":"0001193125-26-076897","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1897662/000119312526076897/ownership.xml","form_type":"4"}},{"id":879183,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37711,"kind":"person","name":"Emany Sravan Kumar","position":1,"cik":"0001897662","reported_name":"Emany Sravan Kumar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:30:04.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":11006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":11006,"source":{"system":"sec-edgar","filing":"0001193125-26-076897","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897662/000119312526076897/ownership.xml","form_type":"4"}},{"id":909253,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":66837,"kind":"person","name":"Pujols Mayobanex","position":1,"cik":"0002109086","reported_name":"Pujols Mayobanex","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-11T21:30:05.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive"}],"balance_after":300000,"derivative":{"exercise_price":8.08,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-046665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526046665/ownership.xml","form_type":"4"}},{"id":939052,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairperson"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T22:00:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":185000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4th of the shares subject to the option shall vest on January 12, 2027, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":185000,"derivative":{"exercise_price":8.23,"expiration_date":"2036-01-11","underlying":"Common Stock","underlying_shares":185000},"source":{"system":"sec-edgar","filing":"0001193125-26-013021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000119312526013021/ownership.xml","form_type":"4"}},{"id":939051,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairperson"}}],"security":"Common Stock","published_at":"2026-01-14T22:00:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":24301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a performance restricted stock unit award of common stock, which will vest upon the Issuer's common stock achieving certain specified prices per share."}],"balance_after":70935,"source":{"system":"sec-edgar","filing":"0001193125-26-013021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000119312526013021/ownership.xml","form_type":"4"}},{"id":939050,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairperson"}}],"security":"Common Stock","published_at":"2026-01-14T22:00:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, 1/4th of the shares subject to which shall vest on January 12, 2027, and 1/4th of the shares subject to the restricted stock unit award shall vest following each one-year period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":46634,"source":{"system":"sec-edgar","filing":"0001193125-26-013021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000119312526013021/ownership.xml","form_type":"4"}},{"id":960795,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T16:43:43.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":7.5,"value":999997.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":869317,"source":{"system":"sec-edgar","filing":"0001104659-25-123597","document":"tm2534053-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000110465925123597/tm2534053-2_4seq1.xml","form_type":"4"}},{"id":961035,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":1,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":2,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":3,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":4,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T16:42:37.000Z","date":"2025-12-18","kind":"purchase","planned":false,"acquired":true,"shares":133333,"price":7.5,"value":999997.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is held by the managing director of Westlake Opportunity GP I, Beth Seidenberg, and whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. Sean Harper, a Reporting Person on Westlake Opportunity's prior Section 16 filings with respect to the Issuer, is no longer a managing director of Westlake Opportunity GP I, and accordingly, is not a Reporting Person on this Form 4."}],"balance_after":869317,"source":{"system":"sec-edgar","filing":"0001104659-25-123596","document":"tm2534053-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465925123596/tm2534053-1_4seq1.xml","form_type":"4"}},{"id":965422,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-12-18T01:30:03.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":false,"shares":23998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the original number of shares subject to the option vested on January 1, 2025, and 1/48th of the original number of shares subject to the option vests in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":85865,"derivative":{"exercise_price":4.83,"expiration_date":"2033-11-05","underlying":"Common Stock","underlying_shares":23998},"source":{"system":"sec-edgar","filing":"0001193125-25-323332","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000119312525323332/ownership.xml","form_type":"4"}},{"id":965421,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-12-18T01:30:03.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":23998,"price":12.2,"value":292775.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions."}],"balance_after":22636,"source":{"system":"sec-edgar","filing":"0001193125-25-323332","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000119312525323332/ownership.xml","form_type":"4"}},{"id":965420,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-12-18T01:30:03.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":true,"shares":23998,"price":4.83,"value":115910.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 12, 2025 in effect at the time of such transactions."}],"balance_after":46634,"source":{"system":"sec-edgar","filing":"0001193125-25-323332","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000119312525323332/ownership.xml","form_type":"4"}},{"id":1097521,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":59798,"kind":"person","name":"GRASSO MARC","position":1,"cik":"0001748894","reported_name":"GRASSO MARC","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-07-01T20:28:49.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 30, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":450000,"derivative":{"exercise_price":3.07,"expiration_date":"2035-06-30","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000950170-25-092421","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748894/000095017025092421/ownership.xml","form_type":"4"}},{"id":1127176,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:40:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080459","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000095017025080459/ownership.xml","form_type":"4"}},{"id":1127175,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:40:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080459","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000095017025080459/ownership.xml","form_type":"4"}},{"id":1127402,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:35:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080457","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017025080457/ownership.xml","form_type":"4"}},{"id":1127401,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:35:50.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080457","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017025080457/ownership.xml","form_type":"4"}},{"id":1127410,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:35:43.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000095017025080456/ownership.xml","form_type":"4"}},{"id":1127409,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:35:43.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1238403/000095017025080456/ownership.xml","form_type":"4"}},{"id":1127954,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43234,"kind":"person","name":"Aktar Mert","position":1,"cik":"0002040256","reported_name":"Aktar Mert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:32:34.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080451","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2040256/000095017025080451/ownership.xml","form_type":"4"}},{"id":1127953,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43234,"kind":"person","name":"Aktar Mert","position":1,"cik":"0002040256","reported_name":"Aktar Mert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:32:34.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080451","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040256/000095017025080451/ownership.xml","form_type":"4"}},{"id":1127345,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:32:13.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080450","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000095017025080450/ownership.xml","form_type":"4"}},{"id":1127344,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":26178,"kind":"person","name":"CLARK IAN T","position":1,"cik":"0001336504","reported_name":"CLARK IAN T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:32:13.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1336504/000095017025080450/ownership.xml","form_type":"4"}},{"id":1127342,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-02T22:30:04.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":65351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":65351,"derivative":{"exercise_price":2.63,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":65351},"source":{"system":"sec-edgar","filing":"0000950170-25-080447","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017025080447/ownership.xml","form_type":"4"}},{"id":1127341,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T22:30:04.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":16634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":16634,"source":{"system":"sec-edgar","filing":"0000950170-25-080447","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017025080447/ownership.xml","form_type":"4"}},{"id":1171934,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-15T21:40:15.000Z","date":"2024-04-11","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":80000,"derivative":{"exercise_price":2.06,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-054342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000095017025054342/ownership.xml","form_type":"4"}},{"id":1171933,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-04-15T21:40:15.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":22636,"source":{"system":"sec-edgar","filing":"0000950170-25-054342","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000095017025054342/ownership.xml","form_type":"4"}},{"id":1171946,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60094,"kind":"person","name":"Biddle Warner Weston","position":1,"cik":"0002034523","reported_name":"Biddle Warner Weston","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-15T17:42:51.000Z","date":"2024-04-11","kind":"grant","planned":false,"acquired":true,"shares":332500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":332500,"derivative":{"exercise_price":2.06,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":332500},"source":{"system":"sec-edgar","filing":"0000950170-25-054345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034523/000095017025054345/ownership.xml","form_type":"4"}},{"id":1171932,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-15T17:42:36.000Z","date":"2024-04-11","kind":"grant","planned":false,"acquired":true,"shares":74000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":74000,"derivative":{"exercise_price":2.06,"expiration_date":"2035-04-11","underlying":"Common Stock","underlying_shares":74000},"source":{"system":"sec-edgar","filing":"0000950170-25-054344","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017025054344/ownership.xml","form_type":"4"}},{"id":1171931,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-15T17:42:36.000Z","date":"2025-04-11","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":55950,"source":{"system":"sec-edgar","filing":"0000950170-25-054344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017025054344/ownership.xml","form_type":"4"}},{"id":1258525,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-19T22:55:53.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":38679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall be fully vested and exercisable on October 30, 2025, subject to the Reporting Person's continuous service to the Issuer as an advisor on and through the vesting date, inclusive."}],"balance_after":38679,"derivative":{"exercise_price":3.03,"expiration_date":"2035-02-14","underlying":"Common Stock","underlying_shares":38679},"source":{"system":"sec-edgar","filing":"0000950170-25-023428","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000095017025023428/ownership.xml","form_type":"4"}},{"id":1295780,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60105,"kind":"person","name":"GEHCHAN NAJI","position":1,"cik":"0002052410","reported_name":"GEHCHAN NAJI","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-24T20:05:04.000Z","date":"2025-01-22","kind":"grant","planned":false,"acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on January 22, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":425000,"derivative":{"exercise_price":3.29,"expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0000950170-25-008961","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2052410/000095017025008961/ownership.xml","form_type":"4"}},{"id":1382040,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":43234,"kind":"person","name":"Aktar Mert","position":1,"cik":"0002040256","reported_name":"Aktar Mert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-10-24T10:05:19.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":87741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary, such that 100% of the shares subject to the option shall be fully vested and exercisable on the third anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":87741,"derivative":{"exercise_price":5.2,"expiration_date":"2034-10-21","underlying":"Common Stock","underlying_shares":87741},"source":{"system":"sec-edgar","filing":"0000950170-24-116840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2040256/000095017024116840/ownership.xml","form_type":"4"}},{"id":1403135,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":11980,"kind":"person","name":"Shaw Christi","position":1,"cik":"0001702473","reported_name":"Shaw Christi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-19T01:16:28.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":66592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on each monthly anniversary, such that 100% of the shares subject to the option shall be fully vested and exercisable on the third anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":66592,"derivative":{"exercise_price":6.89,"expiration_date":"2034-09-16","underlying":"Common Stock","underlying_shares":66592},"source":{"system":"sec-edgar","filing":"0000950170-24-107967","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1702473/000095017024107967/ownership.xml","form_type":"4"}},{"id":1403904,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":60094,"kind":"person","name":"Biddle Warner Weston","position":1,"cik":"0002034523","reported_name":"Biddle Warner Weston","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-18T21:18:53.000Z","date":"2024-09-16","kind":"grant","planned":false,"acquired":true,"shares":2579259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on September 16, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":2579259,"derivative":{"exercise_price":6.89,"expiration_date":"2034-09-16","underlying":"Common Stock","underlying_shares":2579259},"source":{"system":"sec-edgar","filing":"0000950170-24-107968","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2034523/000095017024107968/ownership.xml","form_type":"4"}},{"id":1485262,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T22:56:07.000Z","date":"2024-06-06","kind":"exercise","planned":false,"acquired":false,"shares":9636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter."}],"balance_after":82648,"derivative":{"exercise_price":4.42,"underlying":"Common Stock","underlying_shares":9636},"source":{"system":"sec-edgar","filing":"0000950170-24-071493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000095017024071493/ownership.xml","form_type":"4"}},{"id":1485261,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":71334,"kind":"person","name":"Walker Karen Marie","position":1,"cik":"0002008556","reported_name":"Walker Karen Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2024-06-10T22:56:07.000Z","date":"2024-06-06","kind":"exercise","planned":false,"acquired":true,"shares":9636,"price":4.42,"value":42591.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter."}],"balance_after":9636,"source":{"system":"sec-edgar","filing":"0000950170-24-071493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2008556/000095017024071493/ownership.xml","form_type":"4"}},{"id":1499376,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T16:33:20.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":false,"shares":7146,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":2192,"derivative":{"exercise_price":0.73,"underlying":"Common Stock","underlying_shares":7146},"source":{"system":"sec-edgar","filing":"0000950170-24-065983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017024065983/ownership.xml","form_type":"4"}},{"id":1499375,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T16:33:20.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":false,"shares":10870,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.73,"underlying":"Common Stock","underlying_shares":10870},"source":{"system":"sec-edgar","filing":"0000950170-24-065983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017024065983/ownership.xml","form_type":"4"}},{"id":1499374,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-29T16:33:20.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":true,"shares":7146,"price":0.73,"value":5216.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":43950,"source":{"system":"sec-edgar","filing":"0000950170-24-065983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017024065983/ownership.xml","form_type":"4"}},{"id":1499373,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":80789,"kind":"person","name":"Jones Ryan Alexander","position":1,"cik":"0002007219","reported_name":"Jones Ryan Alexander","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-29T16:33:20.000Z","date":"2024-05-28","kind":"exercise","planned":false,"acquired":true,"shares":10870,"price":0.73,"value":7935.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter."}],"balance_after":36804,"source":{"system":"sec-edgar","filing":"0000950170-24-065983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007219/000095017024065983/ownership.xml","form_type":"4"}},{"id":1644347,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":7356162,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1616348},"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1644346,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1644345,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1644344,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":583,"price":22,"value":12826.0,"ownership":{"direct":false,"nature":"By Vida Ventures III-A, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. (\"Vida III-A\"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":583,"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1644343,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":252553,"price":22,"value":5556166.0,"ownership":{"direct":false,"nature":"By Vida Ventures III, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. (\"Vida III\"). Vida Ventures GP III, L.L.C. (\"Vida III GP\") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any."}],"balance_after":252553,"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1644342,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":94337,"kind":"organization","name":"Vida Ventures, LLC","position":1,"cik":"0001724489","reported_name":"Vida Ventures, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26880,"kind":"organization","name":"Vida Ventures GP III, L.L.C.","position":2,"cik":"0001855502","reported_name":"Vida Ventures GP III, L.L.C.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26881,"kind":"organization","name":"Vida Ventures III, L.P.","position":3,"cik":"0001855504","reported_name":"Vida Ventures III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":26882,"kind":"organization","name":"Vida Ventures III-A, L.P.","position":4,"cik":"0001855503","reported_name":"Vida Ventures III-A, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T00:04:56.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":4523924,"ownership":{"direct":false,"nature":"By Vida Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":4523924,"source":{"system":"sec-edgar","filing":"0000950170-24-015479","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855502/000095017024015479/ownership.xml","form_type":"4"}},{"id":1642756,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:03:04.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":7356162,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Vida Ventures, LLC (\"Vida\"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1616348},"source":{"system":"sec-edgar","filing":"0000950170-24-015473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017024015473/ownership.xml","form_type":"4"}},{"id":1642755,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:03:04.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Vida Ventures, LLC (\"Vida\"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0000950170-24-015473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017024015473/ownership.xml","form_type":"4"}},{"id":1642754,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-15T00:03:04.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Vida Ventures, LLC (\"Vida\"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0000950170-24-015473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017024015473/ownership.xml","form_type":"4"}},{"id":1642753,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":37634,"kind":"person","name":"Cohen Fred E","position":1,"cik":"0001339358","reported_name":"Cohen Fred E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T00:03:04.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":4523924,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Vida Ventures, LLC (\"Vida\"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":4523924,"source":{"system":"sec-edgar","filing":"0000950170-24-015473","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1339358/000095017024015473/ownership.xml","form_type":"4"}},{"id":1642790,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":3349538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":735984},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642789,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4006624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":880364},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642788,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642787,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642786,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":735984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":735984,"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1642785,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T23:56:43.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":3787940,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":3787940,"source":{"system":"sec-edgar","filing":"0000950170-24-015465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000095017024015465/ownership.xml","form_type":"4"}},{"id":1643272,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":3349538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":735984},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643271,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4006624,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":880364},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643270,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":8830901,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1940388},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643269,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Redeemable Convertible Preferred Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":4401771,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":967188},"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643268,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":735984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. (\"Westlake Opportunity\"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC (\"Westlake Opportunity GP I\"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":735984,"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643267,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":24699,"kind":"organization","name":"Westlake BioPartners Fund I, L.P.","position":1,"cik":"0001749591","reported_name":"Westlake BioPartners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24700,"kind":"organization","name":"Westlake BioPartners GP I, LLC","position":2,"cik":"0002007650","reported_name":"Westlake BioPartners GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24703,"kind":"organization","name":"Westlake BioPartners Opportunity Fund I, L.P.","position":3,"cik":"0001811946","reported_name":"Westlake BioPartners Opportunity Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24704,"kind":"organization","name":"Westlake BioPartners Opportunity GP I, LLC","position":4,"cik":"0001811945","reported_name":"Westlake BioPartners Opportunity GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12102,"kind":"person","name":"Harper Sean E","position":5,"cik":"0001541946","reported_name":"Harper Sean E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:35:32.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":3787940,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by Westlake BioPartners Fund I, L.P. (\"Westlake I\"). The general partner of Westlake I is Westlake BioPartners GP I, LLC (\"Westlake GP I\"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any."}],"balance_after":3787940,"source":{"system":"sec-edgar","filing":"0001104659-24-024091","document":"tm246188-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749591/000110465924024091/tm246188-1_4seq1.xml","form_type":"4"}},{"id":1643477,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50600,"kind":"organization","name":"Bain Capital Life Sciences III General Partner, LLC","position":2,"cik":"0001952106","reported_name":"Bain Capital Life Sciences III General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50601,"kind":"organization","name":"Bain Capital Life Sciences Fund III, L.P.","position":3,"cik":"0001875273","reported_name":"Bain Capital Life Sciences Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94313,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III GP, LLC","position":4,"cik":"0001964467","reported_name":"Bain Capital Life Sciences Opportunities III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94314,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III, LP","position":5,"cik":"0001950105","reported_name":"Bain Capital Life Sciences Opportunities III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-02-14T22:26:31.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":12351087,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 12,351,087 shares of the Issuer's Series B Convertible Preferred Stock held directly by Bain Capital Life Sciences Opportunities III, LP (\"BCLS Fund III Opportunities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences III General Partner, LLC (\"BCLS Fund III GP\"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. (\"BCLS Fund III\"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC (\"BCLS Fund III Opportunities GP\"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2713868},"source":{"system":"sec-edgar","filing":"0000950170-24-015358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1875273/000095017024015358/ownership.xml","form_type":"4"}},{"id":1643476,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50600,"kind":"organization","name":"Bain Capital Life Sciences III General Partner, LLC","position":2,"cik":"0001952106","reported_name":"Bain Capital Life Sciences III General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50601,"kind":"organization","name":"Bain Capital Life Sciences Fund III, L.P.","position":3,"cik":"0001875273","reported_name":"Bain Capital Life Sciences Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94313,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III GP, LLC","position":4,"cik":"0001964467","reported_name":"Bain Capital Life Sciences Opportunities III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94314,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III, LP","position":5,"cik":"0001950105","reported_name":"Bain Capital Life Sciences Opportunities III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:26:31.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":22,"value":9900000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents 450,000 shares of the Issuer's Common Stock purchased by BCLS Fund III Opportunities in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences III General Partner, LLC (\"BCLS Fund III GP\"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. (\"BCLS Fund III\"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC (\"BCLS Fund III Opportunities GP\"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":3163868,"source":{"system":"sec-edgar","filing":"0000950170-24-015358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1875273/000095017024015358/ownership.xml","form_type":"4"}},{"id":1643475,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50600,"kind":"organization","name":"Bain Capital Life Sciences III General Partner, LLC","position":2,"cik":"0001952106","reported_name":"Bain Capital Life Sciences III General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":50601,"kind":"organization","name":"Bain Capital Life Sciences Fund III, L.P.","position":3,"cik":"0001875273","reported_name":"Bain Capital Life Sciences Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94313,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III GP, LLC","position":4,"cik":"0001964467","reported_name":"Bain Capital Life Sciences Opportunities III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":94314,"kind":"organization","name":"Bain Capital Life Sciences Opportunities III, LP","position":5,"cik":"0001950105","reported_name":"Bain Capital Life Sciences Opportunities III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-14T22:26:31.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2713868,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 12,351,087 shares of the Issuer's Series B Convertible Preferred Stock held directly by Bain Capital Life Sciences Opportunities III, LP (\"BCLS Fund III Opportunities\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences III General Partner, LLC (\"BCLS Fund III GP\"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. (\"BCLS Fund III\"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC (\"BCLS Fund III Opportunities GP\"), which is the general partner of BCLS Fund III Opportunities. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Opportunities. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Opportunities GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":2713868,"source":{"system":"sec-edgar","filing":"0000950170-24-015358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1875273/000095017024015358/ownership.xml","form_type":"4"}},{"id":340423,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-02-13T22:48:49.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":7746139,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1702036},"source":{"system":"sec-edgar","filing":"0001062993-24-003026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299324003026/form4.xml","form_type":"4"}},{"id":340422,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2024-02-13T22:48:49.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":6890744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1514083},"source":{"system":"sec-edgar","filing":"0001062993-24-003026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299324003026/form4.xml","form_type":"4"}},{"id":340421,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-13T22:48:49.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":910000,"price":22,"value":20020000.0,"ownership":{"direct":true},"balance_after":4126119,"source":{"system":"sec-edgar","filing":"0001062993-24-003026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299324003026/form4.xml","form_type":"4"}},{"id":340420,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":405,"kind":"organization","name":"GILEAD SCIENCES, INC.","symbol":"GILD","position":1,"cik":"0000882095","reported_name":"GILEAD SCIENCES, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-13T22:48:49.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":3216119,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-2 Convertible Preferred Stock and the Series B Convertible Preferred Stock converted into Kyverna Therapeutics, Inc. common stock on a 4.5511-for-1 basis and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects a 1-for-4.5511 reverse stock split, which became effective on January 30, 2024."}],"balance_after":3216119,"source":{"system":"sec-edgar","filing":"0001062993-24-003026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882095/000106299324003026/form4.xml","form_type":"4"}},{"id":1648609,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":false,"shares":12767776,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2805426},"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648608,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"purchase","planned":false,"acquired":true,"shares":450000,"price":22,"value":9900000.0,"ownership":{"direct":false,"nature":"By: Northpond Ventures, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Northpond Ventures GP, LLC (\"Northpond LLC\") is the general partner of Northpond Ventures, LP (\"Northpond Fund\"), and Michael P. Rubin is the managing member of Northpond LLC.  As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any."}],"balance_after":450000,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}},{"id":1648607,"issuer":{"id":5452,"kind":"organization","name":"Kyverna Therapeutics, Inc."},"owners":[{"id":86718,"kind":"organization","name":"Northpond Ventures III GP, LLC","position":1,"cik":"0002010695","reported_name":"Northpond Ventures III GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86719,"kind":"organization","name":"Northpond Ventures III, LP","position":2,"cik":"0001972690","reported_name":"Northpond Ventures III, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":86720,"kind":"person","name":"Rubin Michael P.","position":3,"cik":"0001867627","reported_name":"Rubin Michael P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2024-02-12T17:51:02.000Z","date":"2024-02-12","kind":"exercise","planned":false,"acquired":true,"shares":2805426,"ownership":{"direct":false,"nature":"By: Northpond Ventures III, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the \"Issuer\"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the \"Series B Preferred Stock\"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the \"Common Stock\"). The Series B Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Northpond Ventures III GP, LLC (\"Northpond III LLC\") is the general partner of Northpond Ventures III, LP (\"Northpond Fund III\"), and Michael P. Rubin is the managing member of Northpond III LLC.  As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any."}],"balance_after":2805426,"source":{"system":"sec-edgar","filing":"0000950170-24-014000","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1867627/000095017024014000/ownership.xml","form_type":"4"}}]}